Agoracom Blog Home

Archive for the ‘MedX Health Corporation’ Category

MedX Health $MDX.ca continues its global expansion in the fight against skin cancer $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 5:53 PM on Wednesday, August 12th, 2020
Home - MedX Health

Matthew Bohlsen |

Skin cancer is the most common cancer in the United States and worldwide, but early screening can save lives. Did you know these gruesome facts?

  • One in every three cancers diagnosed is skin cancer.
  • Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year.
  • 1 in 5 Americans will develop skin cancer by the age of 70.
  • More than 2 people die of skin cancer in the U.S. every hour.

Clearly the world needs a much better early skin cancer screening technology.

MedX Health Corp. (TSXV: MDX) is a leading medical device and software company focused on the early detection of skin cancer. MedX has approvals in 35 countries and distribution agreements in place for its key skin cancer diagnostic products – SIAscope and DermSecure™ telemedicine platform.

Following on from MedX’s regulatory approval and distribution agreement in Brazil (read here), the Company recently announced an exciting exclusive distribution agreement to launch SIAscopy on DermSecure™ in Mexico with EMC LABS, S.A.P.I. DE C.V.operating as MedX Mexico. MedX Mexico plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform. MedX Mexico will cover all the upfront costs for application for regulatory approval in Mexico, all marketing costs, and will utilize their large-scale distribution network in Mexico.

MedX Mexico’s, President and CEO, Carlos Vizcaino, states:

“There is a significant opportunity for MedX’s rapid skin assessment technology in Mexico, as skin cancer is a very common type of cancer in Mexico……MedX’s SIAscopy on DermSecure™ Telemedicine platform and advanced SIAscopy imaging technology is a perfect solution to assist dermatologists and physicians in the diagnosis process for early detection of melanoma.”

Masterplan

MedX Health’s masterplan is to continue to rollout distribution agreements with partners globally. So far Brazil and now Mexico are underway. MedX’s revolutionary skin cancer detection device is approved in the USA, Canada, Brazil, Australia, New Zealand, the European Union, Turkey, and many other places. In total MedX’s device has achieved regulatory approval in 35 countries. This means we can expect further distribution agreements in the future to many of the above countries. The potential for future revenues is enormous.

MedX’s business model is similar to Software as a Service (SaaS) companies. The revenue model uses front-end hardware sales coupled with recurring “platform” revenue based on a minimum number of screens per device (360/year at $10/image).

2019 revenues were only small at C$860,248, and 1st quarter 2020 C$95,544, as the Company was impacted by COVID-19 and had yet to ramp up distribution as is now occurring in 2020. For a guide on where revenues are headed the next two years the Beacon Securities report is most useful.

The report’s analysts says MedX has strong visibility on initial orders from the MedX Brazilian distribution partner, that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21. Given that MedX currently trades on a market cap of C$24 million, the C$14 million, if achieved, would mean MedX would trade on a 2022 market cap/sales ratio of only 1.7. Beacon Securities rates MedX Health a ‘buy’ with a Price Target of C$0.45. Given the stock currently trades at C$0.135, the C$0.45 price target represents a very significant upside of 233% or a 3.3 fold gain.

Closing remarks

It is very clear to me that the market is yet to wake up to the potential very large boost in revenues that MedX is working to achieve, now with distribution agreements in both Brazil and Mexico.

Detecting skin cancer is an enormous global need and MedX is working hard to fill this need. MedX has the right device and approvals in 35 countries. All that is needed now is further distribution agreements and revenue to flow. The opportunity for investors to get in early on such a great company with a very bright future still exists. I would not recommend waiting too long as the cheap valuation is unlikely to last long, especially as further new deals are announced.

Source: https://investorintel.com/sectors/biotech-healthcare/biotech-intel/medx-health-continues-global-expansion-fight-skin-cancer/

Stay ahead of skin cancer with early detection SPONSOR: MedX Health $MDX.ca $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 9:00 PM on Sunday, July 26th, 2020

SPONSOR: MedX Health Corporation (MDX:TSX-V) The company has commercialized a highly effective skin cancer scanning device. Patients can receive their prognosis and receive treatment within 72 hours after the initial screening. Initial orders from its Brazilian distribution partner could result in $8M of hardware sales over the next 2 years. Learn More.

Home - MedX Health

Stay ahead of skin cancer with early detection

By Levi Stone, RN, MSN Chief Nursing Officer

Whether it’s lounging by the pool, working in the garden, or watching kids play in the front yard; we find ourselves spending more time outside, soaking in the sunshine. While the sun’s rays have their share of health benefits, they can also create a few troubles as well. Taking a few minutes to routinely check your skin can literally be a life saver. According to the American Academy of Dermatology, skin cancer is the most common cancer in the United States, impacting 1 in 5 Americans during their lifetime. While many types of skin cancers are curable, one type (melanoma) can be deadly if not caught promptly. Working with a dermatologist to “know your spots” can help establish the early detection and subsequent treatments necessary to keep the odds in your favor. It’s also as easy as A-B-C-D-E.

A, for asymmetry. Spots with irregular borders are more concerning opposed to those with a round and symmetrical appearance. Imagine drawing a line in the middle of the spot. If one half doesn’t match the other, it’s a good indication the spot is asymmetrical and should be reported immediately to your dermatologist for further review and assessment.

B, is for borders. The borders on spots and moles should be smooth and even. Melanomas often tend to be more uneven, with edges having a “scalloped” or notched presentation. Best rule of thumb…smooth and round is good, anything else is bad and needs to be checked more closely.

C, represents color. Benign moles tend to be one color and are most often brown. However, when multiple colors are present (such as brown, black, or tan), this may signal a warning that it’s not benign. Melanomas may also become red, white, or blue.

D, is for diameter. In this case, smaller is better usually. While melanomas may start small, they tend to grow to be 6 millimeters or larger. An easy way to evaluate size is compare it to a standard pencil eraser, which is roughly ¼ inch, or 6 millimeters.

E, or evolution. Observing for changes in size, shape, color, and elevation are all characteristics to stay on top of. Bleeding, itching, or crusting are signs of potential trouble as well. Bottom line, if a mole shows ANY signs of changing in ANY way, it’s time to see your dermatologist as soon as possible.

Aside from following the A-B-C-D-E’s of skin cancer, knowing the single most and primary risk factor in developing skin cancer is prolonged exposure to ultraviolet (UV) radiation. Whether it comes from the sun directly, and/or tanning beds, powerful UV rays cause a tremendous amount of skin damage. Sunburns, especially those that are severe (causing blistering and bleeding) exponentially increase these risks. Also, people with fair colored skin, light hair, and light eye color tend to burn more easily and have a greater sensitivity to UV rays making them more susceptible to melanoma. However, skin cancer can and does occur in every race, skin color, and ethnicity.

Lastly, between scheduled dermatology appointments, it’s as important you also take time to personally inspect your skin from head to toe regularly. Melanomas can develop anywhere on the body, including areas that do not get much sun exposure and can be easily missed during an exam. They can also be harder to spot on people with darker colored skin. One of the most famous examples of this involved the legendary Reggae artist, Bob Marley. Having died from melanoma in 1981, his cancer started on his toe. It simply cannot be stressed enough, if you notice changes to your skin, don’t write it off and have it checked as soon as possible. Taking action will not only save that beautiful skin of yours, but possibly your life as well.

Source: https://www.oaoa.com/people/health/levi_stone/stone-stay-ahead-of-skin-cancer-with-early-detection/article_dd341096-c34c-11ea-836a-878e0e58bedb.html

MedX Health $MDX.ca has tons of upside, says Beacon Securities $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 9:38 AM on Monday, July 6th, 2020
Home - MedX Health

By Jayson MacLean

Beacon Securities analyst Doug Cooper thinks the market has so far ignored a series of recent game-changing announcements by medical technology company MedX Health (MedX Health Stock Quote, Chart, News TSXV:MDX).

That scenario, said Cooper in a June 16 update to clients, makes for a prime investment opportunity.

Mississauga, Ontario-based MedX Health is developing non-invasive and cost-effective skin analysis and assessment systems for use by medical professionals. The company’s DermSecure telemedicine platform uses its SIAscopy technology which allows for images to be uploaded and sent to dermatologists for review.

MedX is now through its R&D phase with regulatory approval in 35 countries and has started commercialization.

MedX announced on Monday signing an exclusive distribution agreement to launch SIAscopy on DermSecure in Mexico through what it calls “an aggressive ease-of-access skin scanning/assessment program throughout Mexico” with partner company MedX Mexico.

MedX Mexico said it will be seeking regulatory approval, which it expects will come within the next 60 days, and then commence commercial sales.

According to the company, the opportunity in Mexico is significant, with skin cancer being a very common type of cancer in the country and with MedX’s already-established relationships there.

“MedX Mexico has experience in marketing medical devices and health solutions in the Mexican market, as well as a strong connections with hospitals, major pharmacies and medical clinics which will be a great benefit as it enters into this large market, and we are delighted to be partnering with them,” said Scott Spearn, who, as just announced on Thursday, will be stepping down immediately from the roles of president and CEO of MedX due to family reasons.

On the Mexico deal, Cooper called it, “just the latest in a series of game changing announcements from the company.”

“Yet the stock has yet to react, which we believe creates excellent opportunity for investors. Over the past few months, it has announced new distribution relationships, the imminent commencement of a pharmacy trial in Canada and the closing of a $3.3 million private placement that provided the company with necessary growth capital,” Cooper wrote.

Cooper argued that with its medical device and platform MedX is filling an unmet medical need, where on a global scale melanoma continues to be mis-diagnosed and patients have long wait times to see a dermatologist, a problem as melanoma, if untreated, can become life threatening in as little as six weeks through spread to other parts of the body.

The analyst noted MedX’s Mexican announcement comes on the heels of its exclusive distribution partnership in Brazil (also with a significant skin cancer problem, Cooper says), while on the home front, Cooper said,

“We believe MedX is about to start a trial with a high profile pharmacy chain in Canada. Given the success of the ‘proof of concept’ trial with Boots Pharmacy in Norway, we believe this will not only be successful but will also increase the company’s exposure in the investment community,” Cooper wrote.

The analyst also said he thinks MedX is continuing meaningful conversations with potential partners in the United States and Europe, while also noting there could be an expansion in market opportunity to other conditions such as rosacea, acne and eczema.

Source: https://www.cantechletter.com/2020/06/medx-health-has-tons-of-upside-says-beacon-securities/

CLIENT FEATURE: MedX Health $MDX.ca Commercializing A Highly Effective Skin Cancer Scanning Device $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 11:24 AM on Monday, June 22nd, 2020
Home - MedX Health

MedX Health Corp.  

 (TSX-V: MDX) 

  • Commercialized a regulatory-approved highly effective skin cancer scanning device
  • Provides images that can be uploaded on the company’s proprietary cloud-based tele-health platform and sent to local dermatologists for assessment
  • Patients can receive their prognosis and receive treatment within 72 hours after the initial screening
  • Immanent expansion into Mexico, Colombia and USA
  • Strong relationship with a Canadian national pharmacy chain with ~1,500 stores across the country
  • Initial orders from its Brazilian distribution partner that could result in $8 million of hardware sales over the next 2 years and a run-rate of $14 million of high margin, recurring platform revenue by the end of FY21
  • Dermatologists have declared these images the “next best thing to being there” in person
  • Platform has been proven through a proof-of-concept trial in Norway (109 Boots pharmacies captured 80,000 scans and found 800 cases of melanoma)
  • Company reported revenue of $860,248 for the year ended December 31, 2019

Does This Product Satisfy A Need?

  • Skin cancer accounts for one-third of all cancer cases and is one of the only forms of cancer that is increasing in prevalence
  • Early detection can result in a survival rate of 98%
  • If left undetected, skin cancer and melanoma in particular, metastasizes very quickly, dropping the survival rate down to 25%
  • Rigorous and regular screening regiment now more important than ever

Products

MedX’s SIAscope captures images ‘2mm’ below the skin’s surface

  • Only technology that can capture images below the skins surface
  • The SIAscope is placed directly on the suspicious mole allowing no ambient light to distort the image
  • The fixed focal point and controlled light wavelengths allow for a perfect Dermascopic image as well as 4 additional images
  • The SIAscope is the only scanner in the world that can achieve this

MedX Health Corp. is an advertising client of AGORA Internet Relations Corp.

MedX $MDX.ca Announces Executive Changes

Posted by AGORACOM-JC at 8:09 AM on Thursday, June 18th, 2020
Home - MedX Health
  • President and CEO Scott Spearn has resigned for family reasons, effective immediately
  • Rob von der Porten, Chairman of the Board, has been named interim Executive Chair.

MedX Health Corp. (“MedX”) (MDX – TSXV), announced today that President and CEO Scott Spearn has resigned for family reasons, effective immediately. Rob von der Porten, Chairman of the Board, has been named interim Executive Chair. Mr. Spearn will also be retiring from the Board at or prior to the next AGM. The Board will commence a search for suitable candidates to take on the CEO position.

“The Board thanks Scott for his service and leadership, but we understand his decision to step down,” said Mr. von der Porten. “During his tenure as President and CEO, MedX has completed the development of its SIAscopy™ on DermSecure™ Telemedicine platform, has entered into major distribution arrangements and has significantly strengthened its balance sheet. We wish him the very best. I am confident that under the direction of MedX’s executive leadership team, the Company will enjoy continued success in the future.”

Mr. Spearn noted, “It has been a privilege to have led MedX during an important period of transformation and growth. I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy™ technology and the DermSecure™ Telemedicine platform that represents such a significant development in the diagnosis process for early detection of melanoma.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, Brazil, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005215/en/

Rob von der Porten, Chairman
MedX Health Corp
[email protected]

VIDEO: MedX $MDX.ca #Telemedicine Platform For Skin #Cancer Gets Record Order, Set To Generate Millions In 2020

Posted by AGORACOM-JC at 4:16 PM on Wednesday, June 17th, 2020
Home - MedX Health

MedX (MDX:TSXV) is the “overnight 5-year success story” that most retail investors have never heard about … but that is all about to change in 2020, a year that is set to dwarf the $860,000 in revenue MDX generated in 2019.  

What do they do?  In layman’s terms, they’ve combined their skin cancer scanning device with proprietary software to create a telemedicine platform focused on skin cancer.  In essence, you scan a troubling spot on your body and within 72 hours you can have both a prognosis and treatment completed – god forbid.  

Sounds like a cool idea but does it work?  Glad you asked.  The platform was proven through a proof-of-concept trial in Norway where 109 pharmacies captured 80,000 scans and found 860 cases of melanoma.  

2020 is shaping up to be both the Company’s best year ever and the beginning of something potentially great.  Why?  

1.  MDX signed an exclusive distribution deal that led to the Company receiving its biggest order in history – 500 units.  With much more expected to come due to minimum annual sales requirements.

2.  MDX just did the same thing in Mexico on Monday.  

Mike Druhan, Vice President of Corporate Development, believes more countries are set to follow.  We’d love to tell you more but trust us when we tell you that we’ve saved the best for the interview.  

Telemedicine is going to be a monster, disruptive industry this decade and MDX has the early upper hand in the world of skin cancer.  

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

MedX Health Corp. $MDX.ca Announces 2019 Year End Results

Posted by AGORACOM-JC at 5:08 PM on Friday, June 12th, 2020
Home - MedX Health
  • Company reported revenue of $860,248 for the year ended December 31, 2019

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced its results for the year ended December 31, 2019, which are also available on SEDAR (www.sedar.com).

The Company reported revenue of $860,248 for the year ended December 31, 2019, compared with revenue of $1,087,426 for the year ended December 31, 2018. Sales were lower in 2019 from both its SIAscopy skin assessment technology and therapeutic laser product lines. The Company reported a loss for the year ended December 31, 2019 of $3,276,350 or $0.02 per share compared with a loss of $4,186,573, or $0.03 per share for the year ended December 31, 2018.

For the three months ended December 31, 2019, the Company reported revenue of $181,362, compared with revenue of $275,193 reported in the three-month period in 2018. Revenue was higher than 2018 for the SIAscopy product line in the fourth quarter, while sales of therapeutic lasers were lower for the three-month period. The loss for the three months ended December 31, 2019 was $1,189,458, or $0.00 per share, compared with a loss of $1,015,240, or $0.01 per share for the three-month period ended December 31, 2018.

“The Company reduced spending during 2019 and was able to lower the loss for the year despite a decline in sales, particularly towards the end of the year,” noted Scott Spearn, CEO of MedX. “We are actively working with a number of partners to build revenue from the investment we made in our SIAscopy on DermSecure™ telemedicine platform, that is beginning to gain awareness in significant markets, and the capital we have raised to date in 2020 will enable us to capitalize on these opportunities in 2020 and beyond. While very positive about our future, we have experienced the impact from COVID-19 to date in 2020, particularly with respect to lower sales of our therapeutic laser products, and there is uncertainty as to the timing and extent of its impact during the remainder of 2020,” Mr. Spearn continued.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200612005534/en/

Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229

MedX Health $MDX.ca Joins AGORACOM Platform For Online Marketing And Verified Discussion Forum For Clean Social Media Engagement With Investors

Posted by AGORACOM-JC at 9:08 PM on Monday, June 1st, 2020
MedX Health Corp. (TSXV: MDX) | LinkedIn
  • Announced the launch of a 12 month online marketing campaign through AGORACOM for the purposes of targeting new potential investors that would be specifically interested in the Company’s primary sectors
  • MedX has also launched “CEO Verified” Discussion Forum on AGORACOM to serve as the Company’s primary social media platform to interact with both current and prospective shareholders in a fully moderated environment

TORONTO, JUNE 1, 2020 —  MedX Health Corp. (“MedX” or the “Company”) (MDX:TSXV), a leading medical device and software company focused on skin cancer detection and telemedicine diagnosis, is pleased to announce the launch of a 12 month online marketing campaign through AGORACOM for the purposes of targeting new potential investors that would be specifically interested in the Company’s primary sectors.  MedX is paying $0 in cash for the program thanks to AGORACOM’s cashless and fully compliant shares for services program.      

SIGNIFICANT EXPOSURE THROUGH AGORACOM DIGITAL NETWORK 

In 2019, AGORACOM surpassed 600 million page views, exceeded industry engagement metrics by over 400% and has served over 350 public companies. 

The MedX HUB containing multiple landing pages, videos, photos and other helpful information updated in real-time over the next 12 months can be found at https://agoracom.com/ir/MDX.   

The MedX HUB will receive significant exposure through continuous brand impression, content marketing, search engine marketing and social media engagement throughout the entire AGORACOM network.  AGORACOM is the only small cap marketing firm to hold a Twitter Verified badge, averaging 4.2 million Twitter impressions per month in 2019. 

MODERATED DISCUSSION FOR MEDX MANAGEMENT AND SHAREHOLDERS 

MedX has also launched “CEO Verified” Discussion Forum on AGORACOM to serve as the Company’s primary social media platform to interact with both current and prospective shareholders in a fully moderated environment. 

AGORACOM “CEO Verified” forums provide the small cap industry’s first ever identity verification of company executives on an investor platform.  For the first time ever, small cap CEO’s and officers can post within a discussion forum without the risk of impersonation.  As the ultimate influencers of their own companies, “CEO Verified” Forums create unmatched levels of engagement between management and investors that create civilized, constructive and factual conversation. 

The MedX Forum can be found at https://agoracom.com/ir/MDX/forums/discussion 

VERIFIED MEDX OFFICER AT LAUNCH 

·         Mike Druhan, VP Corporate Development 

Scott Spean, Chief Executive Officer & President stated, “After receiving the largest order in Company history from our Brazilian distributor earlier this year, it became clear to us the time had arrived to finally start raising our brand awareness amongst small cap investors all over North America.  We expect 2020 to be our commercial breakout year and AGORACOM came highly recommended as the firm best capable of accomplishing this goal. As we build our audience of new investors in 2020, I encourage our long-time and loyal shareholders to read and participate in our new CEO Verified Discussion Forum to create great, vibrant and constructive discussion for the long term benefit of everyone. ” 

George Tsiolis, AGORACOM Founder stated “Fans of AGORACOM know very well that 3rd party validation is a very important element of our decision to take on a client. MedX’s success in Brazil this year, as well as, $3,100,000 raised during the most challenging environment in modern history serves as significant evidence of the Company’s strength.  The additional and more important benefit of knowing we will help save lives of thousands of investors in the future was just too great to give up.  We are happy to take their story to the world and encourage shareholders to do the same by participating and sharing the HUB with their networks.” 

SHARES FOR SERVICES 

The Company intends to issue common shares in the capital of the Company to AGORA in exchange for the Services.  Pursuant to the terms of the Agreement, the Company will be issuing a total fee of $60,000 (plus HST), to be paid as follows:  

TERM:                        May 11, 2020 – May 30, 2021 

  • $12,000 + HST Shares For Services upon Commencement May 11, 2020 for initial set up of HUB, marketing materials and search engine programs.
  • $12,000 + HST Shares For Services at end of Third Month August 11, 2020
  • $12,000 + HST Shares For Services at end of Sixth Month November1 1, 2020
  • $12,000 + HST Shares For Services at end of Ninth Month February 11, 2021
  • $12,000 + HST Shares For Services at end of Twelfth Month May 30, 2021

Per TSX Venture Policy 4.3 (Section 6.1), the deemed price of the securities to be issued will be determined after the date services are provided to advertiser in each period and are to be calculated using the closing price on each date above.

About AGORACOM 

AGORACOM is the pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 7.7 million investors that visited 55.2 million times and read over 600 million pages of information over the last 10 years. The average visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.

ABOUT MEDX HEALTH CORP.

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229